We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Arcade is an innovative provider of technology (patent pendinG) that empowers telecom carriers to offer life-changing gigabit broadband over existing networks, with rapid deployment and ROI in under a year. Their solutions enable gigabit speeds everywhere, complementing fiber strategies and avoiding extensive cable replacements.
days to go: Expired investment: £350,000
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
SkiBro is a leading business-to-customer (B2B) Software as a Service (SaaS) platform that aspires to become a contender in the €2 billion ski lessons market. The platform has onboarded 8,000 ski schools and 150,000 ski instructors to date. SkiBro's marketplace encompasses 350 resorts in 7 countries across Europe and North America, with over 6,000 ski instruction products. SkiBro intends to expand into ski hire. The platform has 350 independent ski instructors (250 last year) and 400+ ski schools, with notable ones including ESF La Plagne, ESF Courchevel, Evolution2 (France), Skischule Alberg (Austria), and Ski and Snowboard School Courmayeur (Italy). The company claims that despite COVID-19 hampering business in March 2020, the platform hosted 8.467 lesson bookings worth €1.35 million, recording a 500% YoY growth with an average booking value of €453. SkiBro is seeking £1.5 million of equity funding to accelerate company growth and deliver profitability in 2023-2024.
days to go: Expired investment: £749,825
HotelSwaps is the world’s leading hotel room swap programme that enables owners of independent hotels to swap unused hotel rooms using HotelCoins®. It a technology platform with 420+ active users. It has established partnerships with hotels such as Relais & Chateaux, SiteMinder and Design Hotels. The company 465 hotels members in 64 countries.
days to go: Expired investment: Withheld
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
Founded by entrepreneurs, Oliver Hutley (COO) and Rory Chichester (CEO), TECS Group is an expert provider of technology. TECS Group delivers non-discretionary critical services, such as Electrical Testing and Treatment, Gas Safety, and Fire Safety, on behalf of customers. These services are covered by strict legislation & regulation. Following a constant period of investment into developing a scalable and a solid operating platform, the TECS Group is embarking on its subsequent stage of growth. With the proceeds, the company will deliver and successfully implement its technology strategy, successfully drive for organic sales, increase the national coverage, and continue its final program.
days to go: Expired investment: £96,770
Zap and Go have created ultra fast technology for cordless and hand held devices by using Carbon-Ion technology which result in ultra-fast charging, taking 5 minutes or less. The technology is part derived from Oxford University and in part developed independently by Zap&Go's own scientists.   
days to go: Expired investment: £1,353,551
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph